Yahoo · Oct 7, 2026
Are Options Traders Betting on a Big Move in Grifols Stock?
Investors need to pay close attention to GRFS stock based on the movements in the options market lately.
NASDAQ · GRFS
Grifols, S.A.
Healthcare · Drug Manufacturers - General
$7.17
Up+$0.07 (+0.98%)
Updated Oct 14, 2026, 9:50 PM
SID Score
4.5/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 7.74B
- P/E ratio
- 24.94
- Dividend yield
- 2.41%
- 52-week range
- $6.96 – $9.77
- Volume
- 439.64K
- Avg. volume
- 623.71K
Price performance · GRFS
GRFS price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 13, 2026
GRFS closed at $7.17 after 21 trading sessions, down 2.58% for the selected period.
- Last close
- $7.17
- Period change
- -2.58%
- Period low
- $7.17
- Period high
- $7.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 13, 2026 | $7.36 | $7.36 | $7.15 | $7.17 | 439.64K |
| Oct 12, 2026 | $7.52 | $7.52 | $7.36 | $7.37 | 266.11K |
| Oct 9, 2026 | $7.51 | $7.53 | $7.44 | $7.46 | 330.56K |
| Oct 8, 2026 | $7.42 | $7.45 | $7.2839 | $7.41 | 368.07K |
| Oct 7, 2026 | $7.48 | $7.56 | $7.44 | $7.50 | 260.7K |
| Oct 6, 2026 | $7.53 | $7.565 | $7.415 | $7.52 | 326.1K |
| Oct 5, 2026 | $7.31 | $7.54 | $7.29 | $7.41 | 492.77K |
| Oct 2, 2026 | $7.30 | $7.36 | $7.24 | $7.31 | 390.35K |
| Oct 1, 2026 | $7.29 | $7.33 | $7.195 | $7.30 | 623.13K |
| Sep 30, 2026 | $7.35 | $7.38 | $7.30 | $7.31 | 772.97K |
| Sep 29, 2026 | $7.40 | $7.415 | $7.235 | $7.295 | 485K |
| Sep 28, 2026 | $7.35 | $7.47 | $7.345 | $7.41 | 597.12K |
| Sep 25, 2026 | $7.36 | $7.3891 | $7.2941 | $7.35 | 507.23K |
| Sep 24, 2026 | $7.17 | $7.28 | $7.15 | $7.20 | 536.15K |
| Sep 23, 2026 | $7.33 | $7.38 | $7.19 | $7.195 | 4.07M |
| Sep 22, 2026 | $7.41 | $7.45 | $7.39 | $7.44 | 600.1K |
| Sep 21, 2026 | $7.34 | $7.39 | $7.325 | $7.36 | 356.73K |
| Sep 18, 2026 | $7.37 | $7.41 | $7.29 | $7.31 | 367.75K |
| Sep 17, 2026 | $7.40 | $7.435 | $7.38 | $7.40 | 244.64K |
| Sep 16, 2026 | $7.41 | $7.41 | $7.34 | $7.40 | 471.63K |
| Sep 15, 2026 | $7.40 | $7.4692 | $7.34 | $7.36 | 590.63K |
Latest GRFS news
The latest Smart Investors Daily articles mentioning GRFS.
Stock researchCompany · Overview
Company
Market Activity
Research & News
GRFS research
Overview
Company profile and research snapshot.
Company profile
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | BANCO SANTANDER | Outperform | — |
| Aug 17, 2026 | ALANTRA EQUITIES | Strong Buy | — |
| Jul 29, 2026 | ANALISIS BANCO SABADELL | Overweight | — |
| Jul 27, 2026 | BESTINVER SECURITIES | Buy | — |
| Jul 22, 2026 | CAIXABANK BPI | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 26, 2026
Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings
Grifols has seen a long share price slide in recent years, which naturally puts the focus on one question for investors who still follow the stock. Is the current price tag properly supported by the earnings the business is generating today. Over the past 5 years the share price has fallen 54%, which makes the current valuation story hinge on whether the market has already absorbed weaker sentiment into the earnings multiple. The group’s ability to turn its plasma based operations into...
Yahoo · Sep 24, 2026
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
GRFS vs. SDZNY: Which Stock Is the Better Value Option?
SeekingAlpha · Sep 16, 2026
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
Grifols (GRFS) stock shifts to regional plasma sourcing to boost durable cash generation. Read here for a detailed investment analysis.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
